Persistent luminescent multifunctional drug delivery nano-platform based on nanomaterial ZnGa2O4:Cr3+,Sn4+ for imaging-guided cancer chemotherapy
Persistent luminescent multifunctional drug delivery nano-platform based on nanomaterial ZnGa2O4:Cr3+,Sn4+ for imaging-guided cancer chemotherapy
复制标题
基于纳米材料ZnGa2O4:Cr3,Sn4的持久发光多功能药物递送纳米平台用于成像引导癌症化疗
DOI：
10.1039/c9tb00109c
复制
发表时间：
2019-05-14
影响因子：
7
通讯作者：
Fu, FengFu
中科院分区：
文献类型：
--
作者：
Jiang, Wenjing;Huang, Lin;Fu, FengFu
构建了一种新型的肿瘤靶向、缓释、持续发光的纳米药物载体平台，用于图像引导的肿瘤化疗。该药物缓释纳米平台利用ZnGa 2 O 4：Cr 3+，Sn 4+（ZGCS）纳米粒子实现了对细胞或组织的高信噪比可重复发光成像。在ZGCS表面包覆介孔氧化硅（MS）负载药物，透明质酸（HA）作为看门人和靶向部分。该纳米平台可在红光（550 nm）照射下反复激发产生持续发光，实现细胞或组织的可重复发光成像，无需原位激发，同时对CD-44过表达的癌细胞具有良好的肿瘤靶向能力，并具有透明质酸酶（Hyal-1）响应的可控药物释放。通过使用纳米平台，我们成功地将非荧光化疗药物紫杉醇（Ptx）以0.187 mg mg（-1）的载量和Hyal-1响应性缓释递送到人乳腺癌细胞（MCF-7细胞）中，同时，我们通过发光成像监测纳米平台在靶细胞中的分布和Ptx的释放。该纳米平台具有良好的持续发光特性、肿瘤靶向性和药物释放可控性，有望成为影像引导肿瘤化疗的理想工具，大大提高药物的化疗效率，降低药物的毒副作用。
A novel tumor-targeting and release-controllable drug delivery nano-platform with persistent luminescence was constructed for imaging-guided cancer chemotherapy. The persistent luminescent drug delivery nano-platform employed the persistent luminescent nanoparticles ZnGa2O4:Cr3+,Sn4+ (ZGCS) to realize the repeatable luminescence imaging of cells or tissues with high signal-to-noise ratio. Mesoporous silica (MS) was coated on the ZGCS surface to load drugs, and hyaluronic acid (HA) acted as gatekeeper and targeting moiety. The proposed nano-platform could repeatedly be excited to produce persistent luminescence under red light (550 nm) irradiation to realize repeatable luminescence imaging of cells or tissues without in situ excitation, and simultaneously possessed an excellent tumor-targeting ability towards CD-44 over-expressing cancer cells and controllable drug release with hyaluronic acidase (Hyal-1) response. By using the nano-platform, we have successfully delivered the non-fluorescent chemotherapeutic drug, paclitaxel (Ptx), into human breast adenocarcinoma cells (MCF-7 cells) with a loading capacity of 0.187 mg mg(-1) and Hyal-1 responsive controllable-release, and simultaneously, we monitored the distribution of the nano-platform and the release of Ptx in target cells by luminescence-imaging. The combination of excellent persistent luminescence feature, tumor-targeting ability and controllable drug release makes this nano-platform a promising tool for imaging-guided cancer chemotherapy, which will greatly enhance the chemotherapeutic efficiency of the drug and reduce the side effects.